Abbott Laboratories vs. Rigel Pharmaceuticals Inc. (New)
Rigel Pharmaceuticals Inc. (New) (RIGL) comes out ahead, leading on 5 of 9 compared factors.
Size & Scale
| ABT | RIGL | |
|---|---|---|
| Market Cap | $192.51 billion | $795.39 million |
| Revenue (TTM) | $46.59 billion | $276.79 million |
| Net Income (TTM) | $5.42 billion | $321.91 million |
ABT leads on 3 of 3 size & scale factors.
Valuation
| ABT | RIGL | |
|---|---|---|
| P/E Ratio | 35.72 | 2.51 |
| Price / Book | 3.72 | 1.87 |
| Price / Sales | 4.13 | 2.87 |
RIGL leads on 3 of 3 valuation factors.
Profitability
| ABT | RIGL | |
|---|---|---|
| Net Margin | 11.65% | 116.30% |
| Return on Equity | 10.48% | 75.67% |
RIGL leads on 2 of 2 profitability factors.
Dividend
| ABT | RIGL | |
|---|---|---|
| Dividend Yield | 2.28% | — |
| Payout Ratio | 81.55 | — |
ABT and RIGL split the dividend factors evenly.
Risk & Sentiment
| ABT | RIGL | |
|---|---|---|
| Short Interest | 0.57% | 42.81% |
ABT leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, RIGL overview, RIGL financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.